Drug regulators and ethics: which GCP issues are also ethical issues? (Englisch)
- Neue Suche nach: Bernabe, R. D.
- Neue Suche nach: van Thiel, G. J.
- Neue Suche nach: Breekveldt, N. S.
- Neue Suche nach: van Delden, J. J.
- Neue Suche nach: Bernabe, R. D.
- Neue Suche nach: van Thiel, G. J.
- Neue Suche nach: Breekveldt, N. S.
- Neue Suche nach: van Delden, J. J.
In:
DRUG DISCOVERY TODAY
;
21
, 2
;
217-224
;
2016
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:Drug regulators and ethics: which GCP issues are also ethical issues?
-
Beteiligte:Bernabe, R. D. ( Autor:in ) / van Thiel, G. J. ( Autor:in ) / Breekveldt, N. S. ( Autor:in ) / van Delden, J. J. ( Autor:in )
-
Erschienen in:DRUG DISCOVERY TODAY ; 21, 2 ; 217-224
-
Verlag:
- Neue Suche nach: Elsevier Science B.V., Amsterdam.
-
Erscheinungsdatum:01.01.2016
-
Format / Umfang:8 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 615.1
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 615.1 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 21, Ausgabe 2
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 201
-
The prescription's prescription: enhanced pharmaceutical planning through use of a product health assessmentAshkenazy, R. et al. | 2016
- 204
-
An analysis of FDA-approved drugs: natural products and their derivativesPatridge, E. / Gareiss, P. / Kinch, M. S. / Hoyer, D. et al. | 2016
- 208
-
Key strategic factors for stakeholders in the current global biosimilar marketCasey, D. et al. | 2016
- 212
-
Repurposing historical control clinical trial data to provide safety contextBhuyan, P. / Desai, J. / Louis, M. S. / Carlsson, M. / Bowen, E. / Danielson, M. / Cantor, M. N. et al. | 2016
- 217
-
Drug regulators and ethics: which GCP issues are also ethical issues?Bernabe, R. D. / van Thiel, G. J. / Breekveldt, N. S. / van Delden, J. J. et al. | 2016
- 225
-
Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectivesBulusu, K. C. / Guha, R. / Mason, D. J. / Lewis, R. P. / Muratov, E. / Kalantar Motamedi, Y. / Cokol, M. / Bender, A. et al. | 2016
- 239
-
Why and how have drug discovery strategies in pharma changed? What are the new mindsets?Mignani, S. / Huber, S. / Tomás, H. / Rodrigues, J. o. / Majoral, J. P. et al. | 2016
- 250
-
A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicityScheer, N. / Wilson, I. D. et al. | 2016
- 264
-
Proteomics and drug discovery in cancerDias, M. H. / Kitano, E. S. / Zelanis, A. / Iwai, L. K. et al. | 2016
- 278
-
The role of the 14-3-3 protein family in health, disease, and drug developmentAghazadeh, Y. / Papadopoulos, V. et al. | 2016
- 288
-
In silico methods to address polypharmacology: current status, applications and future perspectivesLavecchia, A. / Cerchia, C. et al. | 2016
- 299
-
Bridging the translational gap: collaborative drug development and dispelling the stigma of commercializationYu, H. W. et al. | 2016
- 306
-
Mapping lifecycle management activities for blockbuster drugs in Japan based on drug approvals and patent term extensionsYamanaka, T. / Kano, S. et al. | 2016
- 315
-
Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitorsSmith, J. R. / Jamie, J. F. / Guillemin, G. J. et al. | 2016
- 325
-
Immunotoxin therapy for hematologic malignancies: where are we heading?Madhumathi, J. / Devilakshmi, S. / Sridevi, S. / Verma, R. S. et al. | 2016
- 333
-
Natural polyphenols: potential in the prevention of sexually transmitted viral infectionsDate, A. A. / Destache, C. J. et al. | 2016
- 342
-
Conformational stability and self-association equilibrium in biologicsClarkson, B. R. / Schön, A. / Freire, E. et al. | 2016
- 348
-
Extensions of indication throughout the drug product lifecycle: a quantitative analysisLangedijk, J. / Whitehead, C. J. / Slijkerman, D. S. / Leufkens, H. G. / Schutjens, M. H. / Mantel-Teeuwisse, A. K. et al. | 2016
- 356
-
Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complexJambhekar, S. S. / Breen, P. et al. | 2016
- 363
-
Cyclodextrins in pharmaceutical formulations II: solubilization, binding constant, and complexation efficiencyJambhekar, S. S. / Breen, P. et al. | 2016
- 369
-
Emerging therapeutic targets for the treatment of hepatic fibrosisFagone, P. / Mangano, K. / Pesce, A. / Portale, T. R. / Puleo, S. / Nicoletti, F. et al. | 2016
- i
-
Contents page 1| 2016
- ii
-
Contents page 2| 2016